Bavarian Nordic A/S  

(Public, CPH:BAVA)   Watch this stock  
Find more results for BAVA
112.00
-2.50 (-2.18%)
Real-time:   3:30PM GMT+2
CPH real-time data - Disclaimer
Currency in DKK
Range 111.00 - 114.50
52 week 63.50 - 136.00
Open 113.50
Vol / Avg. 48,217.00/41,864.00
Mkt cap 2.92B
P/E     -
Div/yield     -
EPS -0.45
Shares 26.11M
Beta     -
Inst. own     -
Nov 13, 2014
Q3 2014 Bavarian Nordic A/S Earnings Release Add to calendar
Sep 25, 2014
Bavarian Nordic A/S Healthacre Trip 2014 with Nordea Add to calendar
Sep 22, 2014
Bavarian Nordic A/S at Maxim Group's Institutional NYC BioDefense Mini-Conference Add to calendar
Sep 17, 2014
Bavarian Nordic A/S Investor Day - 10:30AM GMT+2 - Add to calendar
Aug 28, 2014
Half Year 2014 Bavarian Nordic A/S Earnings Call
Aug 28, 2014
Half Year 2014 Bavarian Nordic A/S Earnings Release
Jun 26, 2014
Bavarian Nordic A/S at CF&B European Midcap Event "Spring" Conference
Jun 24, 2014
Bavarian Nordic A/S UBS Pharma & Healthcare Trip
Jun 19, 2014
Bavarian Nordic A/S at Citi European Healthcare Conference
Jun 12, 2014
Bavarian Nordic A/S Company Day 2014
  

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin 0.42% -3.85%
Operating margin 1.19% 2.76%
EBITD margin - 6.37%
Return on average assets 0.35% -3.12%
Return on average equity 0.49% -4.73%
Employees 426 -
CDP Score - -

Address

Hejreskovvej 10A
KVISTGAARD, 3490
Denmark

Website links

Description

Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in the development, production and marketing of vaccines within biodefence, cancer and infectious diseases therapeutic areas. The Company operates within two segments: Cancer Vaccines and Infectious Disease. The Cancer Vaccines� pipeline is focused on therapeutic vaccines and includes two projects in prostate cancer, PROSTVAC and MVA-BN PRO; two projects in breast cancer, CV-301 and MVA-BN HER2; one project in lung cancer, CV-301 lung, and one project in ovarian cancer, CV-301 ovarian. The Infectious Disease�s pipeline is focused on prophylactic vaccines and includes a smallpox vaccine candidate; an anthrax vaccine candidate, MVA-BN Anthrax, and a RSV vaccine candidate, MVA-BN RSV. Bavarian Nordic A/S has research centers in Mountain View in the United States and Martinsried in Germany, and manufacturing facilities in Kvistgaard, Denmark, and Berlin, Germany.

Officers and directors

Gerard W. M. van Odijk M.D. Chairman of the Board
Age: 57
Paul Chaplin Ph.D. President, Chief Executive Officer
Age: 47
Anders Gersel Pedersen M.D. Deputy Chairman of the Board
Age: 63
Ole Larsen Chief Financial Officer, Executive Vice President
Age: 48
James B. Breitmeyer Executive Vice President, Division President of Cancer Vaccine
Peter Kurstein Director
Age: 57
Claus Braestrup Independent Director
Age: 69
Erik Gregers Hansen Independent Director
Age: 61